Navigation Links
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
Date:4/8/2009

Reference

(1)Lutterbuese, R. et al. (2009). Potent control of tumor growth by CEA/CD3- bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Journal of Immunotherapy, April 1, 2009 [epub ahead of print]

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat cancer, but the therapeutic approaches tested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of BiTE antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treat
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
2. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Genmab Announces HuMax-CD32b Pre-Clinical Program
5. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
6. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
9. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
10. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
11. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK CITY and ... a leading provider of market research reports and solutions, MarketResearch.com ... indicating that 2015 will be a year of market growth ... executives operating a stem cell company or cord blood bank, ... You must analyze market conditions, predict industry trends, and act ...
(Date:3/31/2015)... -- CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... critically-ill and cardiac surgery patients in multiple countries ... results for the fiscal year ending December 31, ... were a record $3.1M, an increase of $2.3M ... $0.8M Highlights for the Year Ending December 31, ...
(Date:3/31/2015)... 2015 Pittcon 2015, the 66th Conference ... on March 12, in New Orleans with an economic ... estimated by the New Orleans Convention and Visitor's Bureau. ... and exhibitor personnel. Those who attended Pittcon for ... For the third year, the co-location of Food Labs ...
(Date:3/31/2015)... YORK , March 31, 2015  PlasmaTech ... company advancing protein biologic therapies and oncology supportive ... partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: 128940) ... country,s Ministry of Food and Drug Safety ("MFDS") ... for MuGard, its oncology supportive-care treatment for the ...
Breaking Biology Technology:MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3
... are very proud to,announce that Cotop International has ... reliability, and a global,distribution network contribute to the ... powerful union of innovative leaders dedicated to the ... 1980 Cotop International was the first company in ...
... an antibody,engineering company developing novel antibodies and ... Technology, today announced the,appointment of Dr. Geert ... has,over 20 years of experience in the ... and development. He comes to f-star,from Baxter ...
... Testing Process Says ... American College of Medical Genetics, BETHESDA, Md., Sept. 25 ... home DNA test kits, tests that can,help determine a person,s ... greater availability of genetic tests and,increased Direct-to-Consumer (DTC) advertising, however, ...
Cached Biology Technology:Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer 2Statement on Direct-To-Consumer Genetic Testing 2Statement on Direct-To-Consumer Genetic Testing 3
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/11/2015)... 2015   The Sync Project™ today ... measure and harness music to improve health. The ... objective measurements of physiology, enabling the study of ... large populations. It is designed for medical and ... rigorous studies and accelerate the discovery of the ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... publisher Springer and Beijing Normal University Press (BNUP) will ... Series. The agreements for the first seven titles of ... Science+Business Media, and Prof. Geng Yang, CEO of BNUP, ... Risk Governance Project (IRG-Project) is supported by both Chinese ...
... WASHINGTON -- A brain study in infant rats ... which could prompt new questions about using the first-line ... Annals of Neurology EarlyView posted online May ... that the anti-epilepsy drug phenobarbital given to rat pups ...
... expecting a demographic explosion in the number of people over the ... expected that 25% of the population will be over the age ... This is a warning call for health authorities and medical ... in age-related chronic diseases such as osteoporosis. In response ...
Cached Biology News:Springer and the Beijing Normal University Press sign agreement on new book series 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
... proteomic service includes protein separation by ... the PDQuest software package from Bio-Rad ... spectrometry. In order to meet customers ... data analysis and format of the ...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: